Bioverativ Inc logo

BIVV - Bioverativ Inc Share Price

$104.98 0.3  0.0%

Last Trade - 08/03/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £898.3m
Position in Universe th / 6415
Bullish
Bearish
Unlock BIVV Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BIVV Revenue Unlock BIVV Revenue

Net Income

BIVV Net Income Unlock BIVV Revenue

Normalised EPS

BIVV Normalised EPS Unlock BIVV Revenue

PE Ratio Range

BIVV PE Ratio Range Unlock BIVV Revenue

Dividend Yield Range

BIVV Dividend Yield Range Unlock BIVV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIVV EPS Forecasts Unlock BIVV Revenue
Profile Summary

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Directors
Last Annual December 31st, 2017
Last Interim December 31st, 2017
Incorporated August 4, 2016
Public Since January 12, 2017
No. of Shareholders: 663
No. of Employees: 460
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 108,223,644
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address 225 2nd Ave, WALTHAM, 02451-1122, United States
Web https://www.bioverativ.com/
Phone +1 781 6634400
Contact ()
Auditors PricewaterhouseCoopers LLP
BIVV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to BIVV
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.